• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov18
Jefferies analyst maintains buy rating on Kiniksa Pharmaceuticals with a target price of $58
14:32
Oct30
Kiniksa Pharmaceuticals International plc CFO Sells Common Stock
20:47
Oct28
Kiniksa Pharmaceuticals released FY2025 9 Months Earnings on October 28 During-Market (EST), with actual revenue of USD 475.44 M and EPS of USD 0.57
20:00
Kiniksa Pharmaceuticals released FY2025 Q3 earnings on October 28 During-Market EST, actual revenue USD 180.86 M (forecast USD 167.36 M), actual EPS USD 0.23 (forecast USD 0.3053)
20:00
Oct21
Kiniksa Pharmaceuticals to Release FY2025 Q3 Earnings on October 28 During-Market (EST), Forecast Revenue USD 167.36 M, EPS USD 0.3069
00:05
Oct17
Kiniksa Pharmaceuticals' Drug KPL-387 Receives FDA Orphan Drug Designation
12:57

Schedules & Filings

Schedules
Filings
Oct28
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 180.86 M, Net Income 18.44 M, EPS 0.23

Jul29
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 156.8 M, Net Income 17.83 M, EPS 0.23

Apr29
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 137.79 M, Net Income 8.539 M, EPS 0.11

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
FJET
8.500
+136.77%
+4.910
AFJK
52.230
+100.81%
+26.220
DJTU
5.160
+83.63%
+2.350
ATHA
6.720
+62.52%
+2.585
SOC
8.250
+56.25%
+2.970
ZNB
1.020
+55.73%
+0.365
VIVK
0.0751
+47.25%
+0.024
SGD
0.2518
+42.26%
+0.075
DJT
14.860
+41.93%
+4.390
VSME
0.1035
+38.37%
+0.029
View More